Atea Pharmaceuticals, Inc.

NASDAQ: AVIR · Healthcare · Biotechnology

PublicHQ Boston, MA · SuffolkCIK 0001593899Reports USD

#235 of 1,418 Healthcare companies by revenuetop-decile growth

EA Score

47D

FH 56DQ 32GM —SS 51

v0.1 · 55/100 weight · provisional

↑ revenue growth (YoY), balance-sheet leverage · ↓ disclosure history, Piotroski F

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$158.3M

Employees

as of 2026-08-12

Market cap

$404.1M

as of 2026-08-12

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$351.4M$351.4M2021

Net income-$158.3M-$158.3M2025

Operating income-$180.9M-$180.9M2025

Total assets$315.2M$315.2M2025

Liabilities$39.8M$39.8M2025

Equity$275.4M$275.4M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Atea Pharmaceuticals, Inc.’s revenue?

Atea Pharmaceuticals, Inc. booked $351.4M in FY2021 revenue, growing 622% year over year — faster than 95% of Healthcare companies we track, at a -45.1% net margin.

Peers · Healthcare

CareDx, Inc78B+Twist Bioscience Corporation70B Arcutis Biotherapeutics, Inc.66B MannKind Corporation69B TruBridge, Inc.75B+Castle Biosciences, Inc.70B

Neighbors

Suffolk →

Vertex Pharmaceuticals Incorporated$12.0B88A American Tower Corporation$935.9M76B+State Street Corporation$13.9B67B NSTAR Electric Company——Toast, Inc.$6.2B67B PTC Inc.$2.7B83B+

Key facts

CEOJean-Pierre Sommadossi

SectorHealthcare

IndustryBiotechnology

HeadquartersBoston, MA

ExchangeNASDAQ: AVIR

Employees55

IPO date2020-10-30

Latest filings

10-Q2026-08-12 8-K2026-08-12 8-K2026-06-22 8-K2026-05-12 10-Q2026-05-12 DEF 14A2026-04-27 8-K2026-03-05 10-K2026-03-05

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.